The reading beside the relationships
Here’s the reading behind the chapters. Each linked title opens a source; the note explains why it’s here. Follow the part you’re curious about. Nobody needs to read the whole shelf in one sitting.
The semaglutide label
Wegovy (semaglutide) uses and warnings. The label defines what the approval covers, including who it’s for.
Semaglutide safety in people
A review of side effects, from common stomach trouble to gallbladder concerns and pancreatitis warnings.
A weight-management trial
A maker-funded trial in adults without diabetes compared semaglutide with placebo, with lifestyle support in both groups. Results are averages.
How long semaglutide stays around
Why semaglutide lasts longer than natural GLP-1, and how the body handles the medicine.
The GHRH family
The natural GHRH message and its relatives. A shared receptor doesn’t give them identical benefits.
The FDA record on discontinued sermorelin
FDA’s finding about discontinued Geref (sermorelin). It doesn’t approve today’s compounded preparations.
Sermorelin’s earlier clinical setting
Earlier sermorelin studies, mostly in children with growth hormone deficiency, including the side effects reported.
The tesamorelin label
Tesamorelin’s HIV-associated use and cautions. The label also rules out general weight-loss management.
The bremelanotide label
Bremelanotide’s approved low-desire condition and population, alongside its blood-pressure and cardiovascular restrictions.
Bremelanotide in controlled trials
Bremelanotide trials in premenopausal women with a defined low-desire disorder. Results concern average changes in desire and related distress compared with placebo.
A second look at the bremelanotide trials
A re-analysis found small effects on desire and distress and questioned how much difference those changes made in everyday life.
Thymosin alpha-1’s isolation
The isolation and sequence work on thymosin alpha-1. Finding a peptide doesn’t establish a treatment.
A larger sepsis trial
A maker-funded sepsis trial found no clear difference in deaths over 28 days compared with placebo.
FDA’s thymosin alpha-1 review
FDA’s thymosin alpha-1 review, including evidence and quality concerns. A review isn’t an approval.
Kisspeptin’s clinical research
Clinical research on kisspeptin. It describes investigational uses, rather than an approved treatment.
The BPC-157 evidence gap
Mostly animal research, with very limited human evidence. Healing claims and long-term safety remain unresolved.
GHK and copper
Natural GHK and its copper-bound form. This review explains the relationship behind the names.
Collagen production in cell cultures
Collagen production in cells grown in a lab. This wasn’t a test of injections in people.
FDA’s peptide safety entries
FDA’s page, current as of April 22, 2026. Withdrawn requests aren’t clearance or approval for compounding.
Compounding and approval
FDA explains why compounded preparations aren’t FDA-approved, even when they share an ingredient with an approved medicine.
How cosmetic oversight differs
Cosmetic oversight differs from drug approval. A skincare context doesn’t establish injection safety.